MARKET

AVBP

AVBP

Arrivent Biopharma Inc
NASDAQ
28.45
-1.65
-5.48%
After Hours: 28.45 0 0.00% 19:30 09/25 EDT
OPEN
30.16
PREV CLOSE
30.10
HIGH
30.55
LOW
28.43
VOLUME
653.15K
TURNOVER
--
52 WEEK HIGH
35.83
52 WEEK LOW
17.00
MARKET CAP
1.40B
P/E (TTM)
-7.7491
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVBP last week (0914-0918)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB), Nuvation Bio (NUVB) and ArriVent BioPharma, Inc. (AVBP)
TipRanks · 09/15 12:30
ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Guggenheim
TipRanks · 09/15 11:35
Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)
TipRanks · 09/15 10:50
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
TipRanks · 09/14 21:10
ArriVent Biopharma granted orphan designation for pancreatic cancer treatment
TipRanks · 09/14 12:20
Weekly Report: what happened at AVBP last week (0907-0911)?
Weekly Report · 09/14 09:00
Weekly Report: what happened at AVBP last week (0831-0904)?
Weekly Report · 09/07 09:00
More
About AVBP
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4.

Webull offers Arrivent Biopharma Inc stock information, including NASDAQ: AVBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVBP stock methods without spending real money on the virtual paper trading platform.